Background: Neopterin and tissue polypeptide-specific antigen (TPS) have been suggested to be useful in differential diagnosis between pancreatic adenocarcinoma (PA) and chronic pancreatitis (CP). The aim of our study was to compare the clinical usefulness of CA19-9, neopterin and TPS serum levels in patients with PA and CP. Methods: The study included 85 patients with PA, 72 with CP and 50 healthy controls. The serum concentrations of neopterin, TPS and CA19-9 were measured (DRG International, USA). The associations of the analyzed markers and clinical data at diagnosis have been evaluated. Results: Serum levels of neopterin, TPS and CA19-9 were higher in PA patients compared to CP (p < 0.001). TPS and CA19-9 levels were also elevated in patients with CP compared to the control group (p < 0.001). In contrast, there was no difference between neopterin serum levels in CP patients and the control group (p > 0.05). Neopterin showed the best sensitivity and specificity (91.8 and 87.5%) in PA diagnosis compared to CA19-9 (respectively 83.5 and 75%) and TPS (75.3 and 65.3%). Conclusion: Our results indicate that neopterin may be potentially useful in differential diagnosis between PA and CP. Assessment of TPS probably adds no significant information to that obtained with CA19-9 and neopterin.

Keywords:
Pancreatic adenocarcinoma, Chronic pancreatitis, CA19-9, Neopterin, Tissue polypeptide-specific antigen
1.
Goonetilleke KS, Siriwardena AK: Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266–270.
2.
Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ: Clinical value of serum CA19-9 levels in evaluating respectability of pancreatic carcinoma. World J Gastroenterol 2008;14:3750–3753.
3.
Bedi MM, Gandhi MD, Jacob G, Lekha V, Venuqopal A, Ramesh H: CA19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol 2009;28:24–27.
4.
Sawabu N, Watanabe H, Yamaguchi Y, Ohtsubo K, Motoo Y: Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas 2004;28:263–267.
5.
Yildrim Y, Gunel N, Coskun U, Pasaoglu H, Aslan S, Cetin A: Serum neopterin level in patients with breast cancer. Med Oncol 2008;25:403–407.
6.
Melichar B, Solichova D, Melicharova K, Malirova E, Cermanova M, Zadak Z: Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006;21:190–198.
7.
Murr C, Widner B, Wirleitner B, Fuchs D: Neopterin as a marker for immune system activation. Curr Drug Metab 2002;3:175–187.
8.
Unal B, Kocer B, Altun B, Surmeli S, Aksaray S, Balci M, Ozlu B, Cengiz O: Serum neopterin as a prognostic indicator in patients with gastric carcinoma. J Invest Surg 2009;22:419–425.
9.
Piecuch J, Rudzki M, Orkisz W, Świetochowska E, Wielkoszyński T, Waniczek D, Arendt j, Sosada K, Żurawiński W, Ładny JR: Neopterin – a potential factor for differentiation between pancreatic cancer and chronic pancreatitis. Hepatogastroenterology 2008;55:258–261.
10.
Birk D, Gansauge F, Gansauge S, Schwarz A, Beger HG: Levels of serum neopterin are increased in pancreatic cancer patients and correlate with the prognosis. Eur J Med Res 1999;4:156–160.
11.
Slesak D, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, Einarsson R, van Dalen A: TPS and CA19-9 measurement in the follow-up of patients with pancreatic cancer and chronic pancreatitis. Int J Biol Markers 2004;19;115–119.
12.
Sandblom G, Granroth S, Ramussen IC: TPS, CA19-9, VEGF-A and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Upsala J Med Sci 2008;113:57–64.
13.
Slesak D, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R: Tissue polypeptide-specific antigen, a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. Cancer 2000;89:83–88.
14.
Yeh LS, Hung YC, Kao A, Lin CC, Lee CC: Tissue polypeptide-specific antigen and carbohydrate antigen 125 in the early prediction of recurrent ovarian cancer. Anticancer Res 2002;22:3669–3671.
15.
Hwa HL, Kuo WH, Chang LY, Wang MY, Tung TH, Chang KJ, Hsieh FJ: Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models. J Eval Clin Pract 2008;14:275–280.
16.
Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E: Diagnostic value of tissue polypeptide-specific antigen in patients with pancreatic carcinoma. Tumour Biol 1994;15:52–60.
17.
Plebani M, Basso D, Del Favero G, Ferrara C, Meggiato T, Fogar P, Mangano F, Ricciardi G, Burlina A: Clinical utility of TPS, TPA and CA19-9 measurement in pancreatic cancer. Oncology 1993;50:436–440.
18.
Kawa S, Tokoo M, Haebe O, Hayashi K, Imai H, Oguchi H, Kiyosawa K, Furuta S, Homma T: Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer 1994;70:481–486.
19.
Banfi G, Zerbi A, Pastori S, Parolini D, Di Carlo V, Bonini P: Behavior of tumor markers CA19-9, CA195, CAM43, CA243 and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 1993;39:420–423.
20.
Joergensen MT, Heegard NH, Schaffalitzky de Muckadell OB: Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer. Pancreas 2010;39:243–247.
21.
Manes G, Spada OA, Rabitti PG, Feola B, Misso S, Minerva A, Uomo G: Neopterin serum levels in pancreatic adenocarcinoma. Int J Pancreatol 1999;25:31–37.
22.
Sahin TT, Yuksel O, Girgin G, Sipahi H, Dikmen K, Azili C, Taneri F, Baydar T: Is neopterin level a predictive and differential biomarker in patients with thyroid disorders? J Endocrinol Invest 2009;32:147–149.
23.
Treska V, Topolcan O, Stanislav K, Liska V, Holubec L: Preoperative tumor markers as prognostic factors of colorectal liver metastases. Hepatogastroenterology 2009;56:317–320.
© 2011 S. Karger AG, Basel and IAP
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.